Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring the ROS1/TRK blocker repotrectinib, which is being investigated for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The company celebrated the results, highlighting that the next-generation tyrosine kinase inhibitor (TKI) achieved a confirmed objective response rate (cORR) of 79% in a TKI-naive subgroup, with a median duration of response (DOR) and progression-free survival (PFS) of 34.1 months and 35.7 months, respectively.
Subgroup Analysis and Treatment Outcomes
In a subgroup of patients who had previous TKI treatment but no chemotherapy, repotrectinib demonstrated a cORR of 38%, with a median DOR of 14.8 months and PFS of 9 months. These results indicate the potential of repotrectinib as an effective treatment option for patients with ROS1-positive NSCLC, particularly in those who have not yet received a TKI.
Implications for ROS1-Positive NSCLC Treatment
The positive outcomes from the Phase I/II trial suggest that repotrectinib may offer significant benefits for patients with ROS1-positive NSCLC, providing a new treatment option with promising response rates and survival durations. Bristol-Myers Squibb’s repotrectinib continues to show potential as a next-generation TKI in the fight against ROS1-positive lung cancer.-Fineline Info & Tech
